- GSK to receive $335.9M up front, ~$552.6M milestones including $27.9M as a commercial milestone and $177.5M related to inventory, making the total value as $1B. Bavarian Nordic to get manufacturing and global rights to GSK’s Rabipur/RabAvert and Encepur vaccines. The transaction is expected to be closed on Dec 31, 2019
- The vaccines will continue to be manufactured at GSK’s Marburg site in Germany to ensure their supply until full production is transferred to Bavarian Nordic. The technology transfer is anticipated to commence in Q1’20 with its expected completion within 5yrs.
- Rabipur (Rabavert in the US & Canada) is a life-saving vaccine indicated for both persons bitten by suspect animals (PEP) or non-immune subjects at risk of rabies (PrEP) while Encepur is indicated for active immunization of high-risk populations against tick-borne encephalitis (TBE)